Answer
Rifampicin 600 mg once daily reduces exposure to selexipag’s active metabolite by half without changing selexipag exposure, and selexipag dose adjustment may be required during concomitant treatment.
Sources for this answer
- Uptravi 200 microgram film-coated tablets (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.5 Interaction with other medicinal products · Version 19Document updated
Sources checked